OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer

OncoSec Medical Inc. , a company developing DNA-based intratumoral cancer immunotherapies, plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer .



from Google News, Yahoo! News, Wikinews, NY Times National News by search term http://ift.tt/1y31hsc

via IFTTT